| INTRODUCTION
Despite introduction of a vaccine for hepatitis B virus (HBV) in 1982, the global burden of HBV remains high, with an estimated 257 million chronic infections globally, of which more than 90% remained undiagnosed in 2015. 1 Accurate diagnosis of HBV is a critical initial step in caring for patients with HBV and preventing new transmissions; however, the diversity of HBV sequences presents a challenge for diagnostic tests. 2 It has been estimated that HBV was first introduced into the human population approximately 33 600 years ago, 3 and since then it has evolved to nine unique genotypes (A-I) and a growing list of more than 30 subgenotypes. [4] [5] [6] This diversity is largely driven by the error-prone viral reverse transcription polymerase, which lacks proofreading abilities and intergenotypic recombination. 6, 7 HBV genotypes and subgenotypes are unevenly distributed, with each HBV genotype predominating in unique regions of the world. 4 In particular, HBV genotype I (HBV-I) has been found in China, [8] [9] [10] [11] India, 12, 13 Laos, 14 and Vietnam, [15] [16] [17] with 39 unique sequences confirmed cases in Asia to date. 5 In addition to these cases, HBV-I strains have also been sequenced from Vietnamese immigrants living in Canada 18 and France, 19 indicating that a more widespread distribution may exist for HBV-I outside of the Asia. Although HBV-I sequences branch together in a phylogenetic tree, recombination analysis has determined that HBV-I sequences are complex recombinants of genotypes A, C, G, and unclassifiable sequences with exact breakpoints varying between individual strains. 7, 8, 12, [14] [15] [16] 18, 20 Classification of these strains as HBV-I or A/C/G/U recombinants is a topic of debate 7, 8, 21, 22 since the classical definition of a unique HBV genotype is at least 8% intergenotypic divergence, yet HBV-I strains are differ from the closest relative, genotype C, by only 7 to 7.9%. 8, 12, 14, 15, 18, 22 Thus, in additional, putative HBV-I genome sequences will be required to determine the appropriate classification for these unique sequences.
HBV coinfection with human immunodeficiency virus (HIV) puts patients at higher risk for severe liver disease, making prevention of such infections a priority. 1 The recent evaluation of HIV pre-exposure prophylaxis (PrEP) regimens by several groups has led to the successful implementation of PrEP programs amongst high-risk populations. 23, 24 Emerging evidence supports the safe use of PrEP amongst HBV carriers. 25 In a recent assessment of the safety of PrEP for patients with active HBV infection, serial blood samples were collected from 12 participants who had chronic HBV infections at the time of enrollment to monitor their infections with and without PrEP treatment during the iPrEx study. 25 HBV sequences obtained from these individuals indicated that resistance mutations did not develop amongst the participants on PrEP, supporting the safe use of PrEP for chronic HBV patients. 25 The samples were collected from diverse geographical regions (United States, Thailand, Peru, Ecuador, and South Africa), although the HBV genotypes for these infections were unknown. To evaluate the HBV diversity encompassed within the iPrEx study, we characterized the sequences generated from serial blood draws of the chronic HBV participants and identified an HBV-I infection among them, which we characterized in depth to expand the known diversity of the genotype I classification.
| MATERIALS AND METHODS

| Samples
The sample cohort has been described previously, 25 and a complete diagnostic profile of the HBV-I infection time course can be found in Figure 1C of Solomon et al. 25 Sequences were generated from leftover cryopreserved plasma collected at the screening visit (day 12), 0, 79, 112, 251, and 336 days timepoints. All specimens were collected with informed consent from donors as approved by the University of California San Francisco IRB.
| Sequencing
Subgenomic sequences were generated for the surface antigen/reverse transcriptase (SRT) region as previously described. 26 The HBV-I genome was amplified in two overlapping fragments using Adventage-2 polymerase reagents (Clontech, Palo Alto, CA). Primer pairs for the S-core fragment were HBV-238F ( Ann Arbor, MI). HBV surface antigen (HBsAg) subtyping was completed as previously described 26 and the Geno2Pheno HBV online tool (Max Planck Institut Informatik, Germany; http://hbv.geno2pheno.org) was used to identify escape and resistance mutations. 14, 15, 18 in BioEdit v7.2.5. 27 Neighbor-joining HBV phylogenetic trees were generated as previously described, 26 
| Phylogenetic analysis
| Serology testing
The HBV-I specimen collected at the study entry day 0 was tested at a 1:500 dilution using ARCHITECT HBsAg Qualitative II, and the ARCHITECT CORE assays, and neat using the ARCHITECT HBeAg assay in combination with the ARCHITECT HBeAg Quantitative Calibrators (Abbott Diagnostics, Abbott Park, IL,) Figure 1A) . Given the limited number of genome sequences available for HBV-I infections, two additional overlapping amplicons were sequenced from the HBV-I specimen to produce a complete genome of 3215 nucleotides. This specimen was collected in Chiang Mai, Thailand, 12 days before patient 9736409 began PrEP treatment, and subgenomic sequences generated from serial samples collected at later timepoints during PrEP treatment were all identical to the sequence obtained from the initial sample. Phylogenetic analysis of the complete genome indicated that the 9736409 sequence branched with other HBV-I reference strains, but was basal to a set of reference strains from China ( Figure 1B) . SimPlot confirmed that the 9736409 sequence shared 95.1% to 99% similarity to a genotype I consensus sequence across the entire length of the genome (Figure 2A) , and recombinant bootscan analysis indicated that it had a U/C recombinant pattern similar to other HBV-I genomes from China and Vietnam ( Figure 2B-D) , 8, 12, 14, 15, 18, 22 with a genotype C region at nucleotide positions 1500 to 2900. Within the HBV surface antigen open reading frame (HBsAg ORF), the HBsAg subtype was determined to be adw2 and an early termination mutation was identified at amino acid 216 (T801A). Likewise, an early stop codon was identified in the precore region of the 9736409 sequence at amino acid 28 (G1896A), which encodes the HBV e antigen (HBeAg). Importantly, no resistance mutations were found in the complete RT ORF as previously noted. 25 The average nucleotide divergence of the 9736409 genome ranged from 7.66% (standard deviation [SD], 0.42%) for n = 1543 genotype C reference sequences 
| Data availability
| DISCUSSION
The unusual complex recombinants classified as HBV-I include a growing number of sequences from individuals born in Asia, where HBV is highly endemic. 4 The HBV-I genotype has been defined by strains having 7% to 8% nucleotide divergence to the closest relative genotype C 8, 12, 14, 15, 18, 22 and the new recombinant genome sequence presented here, 9736409, meets this criteria with a mean nucleotide divergence of 7.66% (SD, 0.42%) to genotype C reference sequences.
Therefore, this sequence is classified as genotype I, making it the first HBV-I strain identified from Thailand. With a HBsAg serotype of adw2, this specimen meets the criteria for the I1 subgenotype. 28 Like other sequences classified as genotype I, 9736409 is a complex U/C recombinant with a similar recombination pattern and breakpoints (1500-2900) as other strains from China and Vietnam ( Figure 2 ). 8, 12, 14, 15, 18, 22 Although other HBV-I strains also have A-and G-like regions [13] [14] [15] [16] [17] (Vietnam refs, Laos, India), these segments could not be classified in the 9736409 genome due to low bootstrap support ( Figure 2) . Notably, genotype G sequences are quite rare in HOLZMAYER ET AL.
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Asia, with all reported strains coming primarily from the United States, France, and Germany. 4 However, a genotype G/C recombinant (CU400) has been reported in Thailand, 29 indicating that genotype G strains might be present in the region. Yet the 9736409 strain is unlikely to be closely related to the CU400 strain since the C-regions of the two sequences have different breakpoints and the two strains only share 89% sequence identity. 29 Consistent with previous HBV-I genome analyses, 8, 13, 16 the region of the 9736409 genome classified as genotype C branched basal to reference strains ( Figure 1C ). This suggests that the recombination events that resulted in HBV-I did not occur recently, although in additional, analysis and sequences will be required to explore the origins of HBV-I further. Likewise, the unclassifiable region from 1 to 1500 ( Figure 2) is distinct from all other HBV genotypes (Figure 2 ), 8 which further supports the identification of I as a separate genotype.
Examination of the amino acid sequences of the 9736409 open
reading frames (ORFs) did not identify escape or resistance mutations in HBsAg or the polymerase. However, an early stop codon was identified in the HBsAg ORF at amino acid position 216 (T801A), which is a naturally occurring variant that results in a 10-amino-acid truncation of the HBsAg ORF. 30 While our direct amplicon sequencing method identified this variant as the major sequence present in 9736409, the possibility cannot be ruled out that a minor population of wildtype virus could produce full length HBsAg in this specimen. In a comparison of all 39 HBV-I genomes with HBsAg and pre-C coverage, only one other strain (LA.KF214679, G668A) carried a nonsense HBsAg mutation, although it is unknown whether HBsAg was detectable in this specimen. 13 Similarly, a minority 
